Post by icemandios on May 24, 2016 12:48:50 GMT
Pulmatrix to Present at 2016 Marcum Microcap Conference
LEXINGTON, Mass., May 24, 2016 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) today announced that its Chief Executive Officer, Robert Clarke, will present an overview of the company, its promising inhaled drug delivery technology, and its pipeline of products to investors at the 2016 Marcum Microcap Conference on Thursday, June 2nd at 11:00 am EDT. The presentation will take place at the Grand Hyatt New York in New York, NY.
As Dr. Clarke will describe, Pulmatrix is rapidly moving ahead with the clinical development of its two lead products: PUR0200, a bronchodilator for chronic obstructive pulmonary disease (COPD); and PUR1900, an inhaled drug to fight fungal infections in the lungs. In addition, Dr. Clarke will describe some of the pre-clinical Pulmatrix pipeline activities with particular focus on opportunities in idiopathic pulmonary fibrosis (IPF).
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
LEXINGTON, Mass., May 24, 2016 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) today announced that its Chief Executive Officer, Robert Clarke, will present an overview of the company, its promising inhaled drug delivery technology, and its pipeline of products to investors at the 2016 Marcum Microcap Conference on Thursday, June 2nd at 11:00 am EDT. The presentation will take place at the Grand Hyatt New York in New York, NY.
As Dr. Clarke will describe, Pulmatrix is rapidly moving ahead with the clinical development of its two lead products: PUR0200, a bronchodilator for chronic obstructive pulmonary disease (COPD); and PUR1900, an inhaled drug to fight fungal infections in the lungs. In addition, Dr. Clarke will describe some of the pre-clinical Pulmatrix pipeline activities with particular focus on opportunities in idiopathic pulmonary fibrosis (IPF).
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare disease like cystic fibrosis. Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.